Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy

Background: Immune checkpoint inhibitors (ICIs) targeting PD-1 or PD-L1 improved the survival of non-small cell lung cancer (NSCLC) patients with PD-L1 expression ≥50% and without alterations in EGFR, ALK, ROS1, RET. However, markers able to predict the efficacy of ICIs, in combination with PD-L1 ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Cefalì, Marco, Epistolio, Samantha, Ramelli, Giulia, Mangan, Dylan, Molinari, Francesca, Martin, Vittoria, Freguia, Stefania, Mazzucchelli, Luca, Froesch, Patrizia, Frattini, Milo, Wannesson, Luciano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954500/
https://www.ncbi.nlm.nih.gov/pubmed/35329953
http://dx.doi.org/10.3390/jcm11061627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954500/
https://www.ncbi.nlm.nih.gov/pubmed/35329953
http://dx.doi.org/10.3390/jcm11061627

Ejemplares similares